HCM
TEVA icon

Hollencrest Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hollencrest Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$7.8K – 1297
2025
Q4 		$7.8K Buy
+250
New +$6.16K ﹤0.01% 848
2025
Q1 		– Sell
-216
Closed -$4.76K – 1238
2024
Q4 		$4.76K Hold
216
– – ﹤0.01% 901
2024
Q3 		$3.89K Hold
216
– – ﹤0.01% 889
2024
Q2 		$3.51K Hold
216
– – ﹤0.01% 880
2024
Q1 		$3.05K Hold
216
– – ﹤0.01% 858
2023
Q4 		$2.25K Hold
216
– – ﹤0.01% 878
2023
Q3 		$2.2K Hold
216
– – ﹤0.01% 908
2023
Q2 		$1.63K Buy
+216
New +$1.75K ﹤0.01% 985

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hollencrest Capital Management's TEVA Position: Q1 2026 in Review

Hollencrest Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 250 shares — an estimated $7.8K sold.

Hollencrest Capital Management first reported a position in TEVA in Q2 2023 and held it in 8 quarters. The position peaked at $7.8K in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Hollencrest Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hollencrest Capital Management sold 250 Teva Pharmaceuticals shares in Q1 2026, an estimated $7.8K.
  • Hollencrest Capital Management first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Hollencrest Capital Management's Teva Pharmaceuticals position peaked at $7.8K in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Hollencrest Capital Management's 13F filing for Q1 2026, filed 7 May 2026.